Publications

Debio 0123-101, a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors: safety, pharmacokinetic, and…

Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of…

Debio 0123, A Selective WEE1 Inhibitor in Clinical Development for Patients with Solid Tumors

Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase 1 clinical trial

The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models

First-in-Human phase 1 study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced…

Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123